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SUMMARY
Objective: The aim of this study was to explore how patients obtain the information and education on the 
use of asthma medications.
Material and methods: The study was conducted as a survey in 2010 (n=1207) and 2016 (n=956) during one 
week on September with individuals purchasing asthma and allergy drugs in Finnish pharmacies all around the 
country. The study participants were asked from where (physician, nurses, pharmacists, patient associations, 
courses or books and journals) they received information concerning asthma drugs and how much informa-
tion they had received. The respondents were divided into most severely ill (MSI, emergency care or hospital 
care for asthma) and less severely ill asthma patients (LSI, the other asthma patients without emergency care). 
Results: Physicians were the most frequent source of information for the MSI asthma patients (60% of pa-
tients), followed by pharmacists (55%) and nurses (45%). Pharmacists informed more equally the most severely 
ill asthma patients (MSI) and LSI asthma patients. All in all, 7% of the MSI patients and 21% of the LSI patients 
reported not having received any information either from physicians, nurses or pharmacists.
Conclusions: Pharmacy personnel distribute regularly information on asthma medication and this should 
be further strengthened. Although most of the asthma patients recalled having received information on their 
asthma drugs still every fifth patient reported not having received any information. It is important to con-
tinuously pay attention to proper education for guided self-management and to further improve sources for 
asthma information in order to achieve good asthma control.
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INTRODUCTION
Adherence of asthma patients to their medication is 
crucial for symptom control and to prevent exacer-
bations. Nevertheless, a significant proportion of pa-
tients have insufficient adherence to the medications 
or use the medication improperly or have both (Sin-
clair et al. 1987, Diamond and Chapman 2001, Schulz 
et al. 2001, Barber et al. 2004, Gregoriano et al. 2018).
It has been repeatedly demonstrated that suffi-
cient patient information and education on disease 
improves treatment adherence and asthma control, 
leading to substantially better outcomes (Cordina et 
al. 2001, Barbanel et al. 2003, Bunting and Cranor 
2003, Gregoriano et al. 2018, Stanford et al. 2019). 
However, there are only few reports on the access, 
amount, sources, and the matching of the informa-
tion and education on disease with the needs of spe-
cific patient populations (Närhi et al. 2001).
To support the well-being of patients with asth-
ma, to decrease disease severity and mortality and to 
control the economic burden, a comprehensive Finn-
ish National Asthma Programme (FNAP) was imple-
mented in Finland 1994–2004 (Haahtela et al. 2006). 
As the patients’ empowerment for the success of the 
treatment is essential, the FNAP emphasized self-
management guided by physicians, nurses and phar-
maceutical personnel. Therefore, the FNAP recom-
mended establishing of a specialized asthma nurse 
and pharmacist network in the Primary Health Care 
and pharmacies. However, little is known what is the 
current distribution of the patients’ self-management 
guidance between the networks and professions, and 
specifically, how the pertinent information and edu-
cation on disease has been delivered to the patients.
The current study explores how patients obtain 
information and education on asthma and on the 
use of asthma medications – what are the sources 
and amount of the information and education. The 
primary hypothesis of the study was that physicians 
are the most common source of the information and 
education on asthma, followed equally by nurses and 
pharmaceutical personnel, with only negligible im-
pact from other sources. Secondary hypothesis was 
that the most severely ill (MSI) patients obtain more 
extensive information from each of the sources than 
their less severely ill (LSI) counterparts. 
MATERIAL AND METHODS
The present asthma study was a part of a large na-
tionwide allergy and asthma survey. Allergy Barom-
eter questionnaires were given to all individuals pur-
chasing asthma and allergy drugs in pharmacies all 
around Finland in September 2010 and 2016 (Kauppi 
et al. 2015, Jantunen et al. 2018). The Allergy Barom-
eter is a questionnaire on demography (gender, edu-
cation), diagnosis, specific allergy- and asthma-relat-
ed symptoms and medications, precipitating factors, 
the participants’ subjective perceptions on the sever-
ity of their disease, tobacco smoking, use of Health 
Care Services, received guided self-management ad-
vice and opinions on the need of information of asth-
ma and asthma medication. In 2010 patients were also 
asked if they like to make an appointment with phar-
macy personnel for the information and education of 
asthma drugs. The patients were enquired how much 
they had received information on allergy or on asthma 
from physicians, nurses, pharmacies, patient organiza-
tions, courses and books. Internet as a source for in-
formation was enquired in the survey only in 2016. In 
addition, they were enquired which of the following 
they found difficult (taking medication at time, under-
standing instructions for use, inhalation technique, 
safety of medication, or not having problems or some 
other problem (if so, what it would be). Pharmacies 
were asked to enroll the first five patients purchas-
ing asthma and allergy medication during the week. 
The inclusion criteria for the asthma branch were: 
age 16–75 years, diagnosis of asthma, and special re-
imbursement for asthma medication. Based on their 
current medication, patients with the Chronic Ob-
structive Pulmonary Disease were excluded.
The patients who were treated in the emergency 
room or who had at least one day hospital care with-
in the last year were defined as the most severely ill 
(MSI). All the other asthma patients were categorized 
into the less severely ill (LSI) group. From altogether 
1 207 responders in 2010, 538 patients (n=66 for the 
MSI and n=472 for the LSI group) were eligible for 
the analysis (Figure 1). In 2016 956 responses were 
received and 492 of them were included in the study 
(n=77 for the MSI and n=415 for the LSI group). Re-
sults in 2010 and 2016 are presented as sums of both 
years if the study year is not mentioned.
Statistical significances of differences between the 
sources of the information and education for MSI 
and LSI patients were assessed with Pearsons’ chi 
square independence test. P values of <0.05 were 
considered statistically significant. 
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Table 1. Sources of information and education for asthma patients (% of responded, sum of years 2010 
and 2016). MSI = severely ill asthma patients (emergency care or hospital care for asthma) and LSI = less 
severely ill asthma patients (the other asthma patients without emergency care).
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
Not at all
Some
Quite a lot
A lot
MSI
%
n=140
13 
27 
25 
35 
n=134
33 
22 
26 
19 
n=133
20 
25 
30 
25 
n=122
86 
8 
5 
1 
n=122
93 
2 
2 
2 
n=128
38 
25 
23 
15 
n=71
34
28
24
14
LSI
%
n=840
44 
21 
21 
14 
n=811
62 
18 
12 
8 
n=828
33 
31 
24 
12 
n=780
90 
5 
3 
2 
n=781
94 
2 
2 
2 
n=823
39 
31 
20 
10 
n=381
50
23
17
9
All
%
n=980
39 
22 
22 
17 
n=945
58 
19 
14 
9 
n=961
31 
30 
25 
14 
n=902
89 
6 
3 
1 
n=903
94 
2 
2 
2 
n=951
39 
30 
20 
11 
n=452
48
24
18
10
Pearsons’ 
χ² -test (p)
< 0.001
< 0.001
< 0.001
0.436
0.878
0.227
0.069
Physician 
Nurse
Pharmacy personnel
Patient organizations
Courses 
Books, journals etc.
Internet (only 2016)
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RESULTS
Of all sources of information and education on asth-
ma medication received by the MSI patients, the 
most abundant source was physicians (60% with 
quite a lot or a lot of information altogether). This 
was followed by pharmacists (55%), nurses (45%), 
books or journals (38%), patient associations (6%) 
courses (4%) and the internet 38% (assessed only in 
2016) (Table 1, Figure 2 and 3). In 2010, 78% of the 
respondents were women and in 2016, 79% of the 
respondents were women (p non-significant (ns)). 
Likewise, the mean age of the respondents was 52.5 
years (SD 14.7) in 2010 and 54.5 (SD 14.8) in 2016 (p 
= 0.031). Distribution of education level of the re-
spondents were similar in both years. Of the re-
spondents in 2010, 23% had received university de-
gree and 29% in 2016, correspondingly (p ns). 
The MSI patients received information statistically 
significantly more often than their LSI counterparts 
from physicians and nurses in 2010 and 2016, and 
from pharmacy in 2016. No such differences were 
found for other sources. Of the MSI patients, 20% 
reported not having received any information from 
the pharmacy, while corresponding figure for physi-
cians was 13% and for nurses 33% (Table 1, Figure 2).
Of the LSI patients, 35% reported having received 
quite a lot or a lot of information from physicians, 
36% from pharmacists, and 20% from nurses. Of the 
LSI patients, 33% reported not having received any 
information from the pharmacy. Of the LSI patients, 
44% reported not having received any information 
from physicians and 62% from nurses. Of all asthma 
patients 19% (7% of MSI, 21% LSI patients) report-
ed not having received any information either from 
physicians, nurses or pharmacist (Table 1, Figure 2). 
In the group of LSI patients, information given by 
nurses had increased significantly (a lot or quite a lot 
from 17% in 2010 to 23 % in 2016) and information re-
ceived from books and journals had decreased (a lot 
or quite a lot from 35 % in 2010 to 25 % in 2016). In 
the group of MSI patients, corresponding differences 
were not detected (Table 1, Figure 2).
58% of the MSI patients and 54% of LSI patients (in 
2010), considered that a scheduled appointment with 
pharmacy personnel for the information and educa-
tion on the medication was desirable.
DISCUSSION
In this study, physicians were the most frequent 
source of the information and education of asthma, as 
expected. What was unexpected was the higher pro-
portion of the information given by the pharmaceuti-
cal personnel than that provided by nurses. Further-
more, while the physicians and nurses seem to focus 
mostly on the MSI patients, the pharmacy personnel 
divided their effort more equally between the MSI and 
LSI patients. Moreover, one fifth of all the patients re-
ported not having received any information and edu-
cation whatsoever from the health care professionals. 
Of other sources, such as the books, journals and the 
internet were also important, whereas patient organi-
zations and courses had only minor impact.
In 2001, 69% and 23% of the study participants had 
appointment with a physician or a nurse, respective-
ly (Haahtela et al. 2006). In 2010, the corresponding 
figures remained unchanged, 65% and 22% (Jantunen 
et al. 2018) indicating an information and education 
gap in the Primary Care. However, all of these pa-
tients were in contact with pharmaceutical person-
nel when buying their asthma medication which of-
fers to the latter an opportunity to reduce this gap. 
Nevertheless, it seems that in some cases the infor-
mation and education was not provided by the phar-
macy personnel either, despite the requirement of 
Finnish legislation for pharmacy personnel to ensure 
the proper and safe use of the dispensed medicines 
(Medicines Act 395/1987). Probably limited time for 
one patient or insufficient guidance to patient edu-
cation may prevent proper information and educa-
tion from pharmacy personnel. Reluctance to receive 
information or rush may be obstacles from the pa-
tient perspective. 
It is not surprising that physicians and nurses, 
who are aware of the severity of illness of their pa-
tients, invest – in accordance with the patients’ need 
– more information and education work in the MSI 
than in the LSI populations. Since the pharmaceuti-
cal personnel do not have such data on the disease, 
they seem to divide the information and education 
more equally between the MSI and LSI. Neverthe-
less, for the MSI patients, pharmacists represent the 
second most important source of information and 
education.
For the LSl patients, the pharmacy personnel and 
physicians were an equally important source of infor-
mation and education. The role of information and 
education delivered by pharmacy personnel appears 
to be a valuable resource, which is worth of further 
development to secure access of pertinent informa-
tion and education for both MSI and LSI patients. 
This would be in concert with the opinion of the pa-
tients surfaced in our study.
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Figure 1. Patient selection to the study population.
Returned questionnaires
n=1207 (2010); n=956 (2016)
Patients with physician diagnosed asthma 
n=892 (2010); n=750 (2016)
Patients with specially reimbursed 
medicines for asthma 
n=720 (2010); n=570 (2016)
COPD excluded
n=636 (2010); n=514 (2016)
Age 16−75 years 
n=538 (2010); n=492(2016)
Patients with COPD
n=84 (2010)
n=56 (2016)
Age under 
16 years
n=98 (2010)
n=22 (2016)
The most severly  
ill patients (MSI)
–  ≥1 emergency room visits or ≥1 
hospital stay due to asthma  
during the previous year
n=66 (2010)
n=77 (2016)
Less severly  
ill patients (LSI)
Neither emergency room  
visits nor hospitalizations during  
the previous year
n=472 (2010)
n=415 (2016)
↓
↓
↓
↓ ↓
↓
↓
↓
©  DOSIS      2/2019 ©  Suomen Farmasialiitto ry112
Figure 2. The information source for asthma and asthma medication reported by the most severely ill ast-
hma patients (MSI) and less severely ill asthma patients (LSI) in 2010 and 2016. 0 = no information, 1= so-
me information, 2= quite a lot, 3 = a lot of information.
  
Figure 2. The information source for asthma 
and asthma medication reported by the most severely ill asthma patients (MSI) and less 
severely ill asthma patients (LSI) in 2010 and 2016. 0 = no information, 1= some information, 
2= quite a lot, 3 = a lot of information.  
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Besides the severity of the disease, there are also 
other factors that have been earlier identified as a risk 
for insufficient information and education in asthma. 
These include age (65 years or more), male sex, long 
history on medication and new medicines (Närhi et 
al. 2001, Barber et al. 2004, Puumalainen et al. 2005). 
However, this is contradictory to expectations, since 
it could be expected that in association to medica-
tion changes the patient would receive more infor-
mation. Structured and motivational asthma infor-
mation and education programs should be brought 
into use. Such protocols can successfully be delivered 
by pharmacies, as shown in numerous studies (Närhi 
et al. 2001, Fathima et al. 2013, Ottenbros et al. 2014). 
For better allocation of resources, pharmacies would 
also benefit from validated screening tools to identify 
patients with specific need of information and edu-
cation. These tools are already available but their use 
should be implemented in daily practice (LeMay et 
al. 2014, Naik-Panvelkar et al. 2015). Further, eHealth 
solutions should be rigorously developed and imple-
mented to ensure availability and affordability of in-
formation and education for this patient population. 
One limitation of the current study was the ab-
sence of the Internet as a source of information and 
education in the earlier Allergy Barometer question-
naire. It is likely, however, that the responders inter-
preted the alternative “Books, journals etc.” broadly 
enough and the Internet-delivered information was 
included. 
This study included relatively small number of the 
MSI patients which was a limitation, too. However, 
the sample is representative as its MSI/LSI patients 
ratio is in line with earlier asthma barometer studies 
(Kauppi et al. 2015). Further, a visual analogue scale or 
a numerical rating scale might have given a more pre-
cise results on amount of given information (Salo et 
al. 2016). Recall bias, on the other hand, may have an 
impact on the results. Thus, it is possible that amount 
of given information is larger and it is offered more 
Figure 3. The internet as an information sour-
ce for asthma and asthma medication reported 
MSI and LSI asthma patients (LSI) in 2016. 0 = 
no information, 1= some information, 2= quite 
a lot, 3 = a lot of information.
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often to the patients than reported here. 
One of the achievements of the Finnish National 
Asthma Programme (FNAP) was a consensus on the 
task division and collaboration between physicians, 
nurses and pharmacists regarding the information 
and education for patients with asthma (Haahtela et 
al. 2006). When physicians and nurses educated pa-
tients for asthma and guided self-management, phar-
macy personnel focused more on inhalation tech-
nique and proper use of devices. Since the launch 
of the National Guidelines emphasizing guided self-
management, the morbidity and mortality due to 
asthma have decreased (Haahtela et al. 2006). This 
might explain the relatively small proportion of MSI 
patients in this study which is in line with the overall 
significant decrease of self-reported asthma severity 
within the last decade, as demonstrated by earlier 
Finnish studies (Browatzki et al. 2009, Pallasaho et 
al. 2011, Kauppi et al. 2015).
CONCLUSIONS 
Pharmacy personnel is a significant source of infor-
mation and education for asthma patients. This role 
should be strengthened by introducing new tools 
and practice support for pharmacies especially con-
idering the enlarging group f drugs an  inhalers for 
asthma patients in the recent years. I  is important 
to continuously pay attention to proper education 
for guided self-management and to further improve 
sources for asthma information and education in or-
der to achieve good asthma control.
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Taustaa: Tämän tutkimuksen tavoitteena oli selvit-
tää, kuinka potilaat saavat tietoa ja ohjausta astmaan 
ja astmalääkkeisiin. 
Aineisto ja menetelmät: Aineisto koostuu kahdes-
ta kyselystä, jotka kumpikin toteutettiin apteekeissa 
yhden viikon aikana syyskuussa 2010 ja syyskuussa 
2016. Tutkimukseen vastasi 1 207 henkilöä vuonna 
2010 ja 956 henkilöä vuonna 2016. Vastaajilta kysyt-
tiin, mistä he olivat saaneet tietoa astmasta ja ast-
malääkkeistä (lääkäriltä, hoitajalta, apteekista, poti-
lasyhdistyksiltä, kursseilta tai kirjoista ja lehdistä) ja 
kuinka paljon he olivat saaneet tietoa astmasta. Po-
tilaat jaettiin vaikeaa astmaa sairastaviin (päivystys-
käynti tai sairaalahoito astman vuoksi) ja lievempää 
astmaa sairastaviin (muut astmapotilaat). 
Tulokset: Vaikeaa astmaa sairastavat saivat useimmin 
tietoa lääkäriltä (60 %), apteekeista (55 %) tai hoitajil-
ta (45 %). Apteekit jakoivat tietoa tasaisemmin vaike-
aa astmaa sairastaville ja lievää astmaa sairastaville. 
Tutkimuksen tulosten mukaan 7 prosenttia vaikeaa 
astmaa sairastavista ja 21 prosenttia lievää astmaa sai-
rastavista eivät kokeneet saaneensa tietoa sairaudes-
taan lääkäriltä, hoitajalta eikä apteekista. 
Johtopäätökset: Apteekkien henkilökunta jakaa 
tietoa astmalääkkeistä säännöllisesti, ja tätä pitäisi 
edelleen lisätä. Vaikka suurin osa astmaa sairastavis-
ta oli saanut tietoa astmasta ja astmalääkkeistä, sil-
ti noin joka viides koki, ettei saanut mitään tietoa. 
On tärkeää jatkuvasti kiinnittää huomiota ohjatun 
omahoidon neuvontaan ja edelleen parantaa astman 
hoito-ohjeiden saatavuutta hyvän astman hallinnan 
saavuttamiseksi. 
 
Avainsanat: apteekki, astma, farmaseutti, lääke, 
lääkeohjaus
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